Top Emerging Cardio Vascular Devices Companies - 2022
Micro Interventional Devices: Safe Percutaneous Interventions to Achieve Surgical Efficacy

Top 10 Emerging Cardio Vascular Devices Companies - 2022

Bouncing back to the pre-pandemic levels, the cardiovascular devices market is gaining traction with the advancements driven by artificial intelligence (AI), big data, the internet of medical things (IoMT), and augmented and virtual realities (AR/VR).

The growth of the cardiovascular devices market is primarily attributed to the increasing adoption of advanced treatment techniques, like transcatheter aortic valve replacement (TAVR), transcatheter mitral valve repair and replacements (TMVR), and transcatheter tricuspid valve repair and replacements (TTVR). These percutaneous procedures are swiftly replacing surgical methods and making cardiac treatments possible even for patients who could not tolerate conventional heart surgeries. As a result of these trends, the cardiovascular devices market is projected to grow from last year’s $54.08 billion to $86.27 billion in 2028, at a CAGR of 6.9 percent.

To put the spotlight on such key developments in the industry, MedTech Outlook highlights the key developments in cardiovascular devices and how healthcare providers leverage them in diagnostics and treatment for enhanced monitoring and therapeutic outcomes. The edition features thought leadership articles from Michael Dale, Senior Vice President at Abbott, Beate Graeter, Director of Sterile Processing at CaroMont Health, Marco Dolci, President of Cardiopulmonary at LivaNova, and Thomas Draper, Vice President of Cardiovascular division at Wellstar Health System, who throw light on the recent advancements in cardiovascular devices and how they improve the capabilities in treating cardiovascular diseases.

In this edition of MedTech Outlook magazine, we also bring to you the story of some of the top emerging cardiovascular devices companies that deliver the best outcomes for their clients, including BioSig Technologies and Micro Interventional Devices (MID). While BioSig is unlocking the future of bioelectronic medicine with its pioneering signal processing solutions, MID is revolutionizing the treatment of structural heart diseases. MID’s products for transcatheter cardiac repair (TCR) procedures successfully replicate established surgical structural heart repair procedures percutaneously.

Through the following pages, we aim to shine a light on the innovative trends and latest developments in the cardiovascular devices industry.

We would like to know your thoughts.

    Top Emerging Cardio Vascular Devices Companies

    Micro Interventional Devices, Inc.
    Micro Interventional Devices (MID) designs, develops, and manufactures minimally invasive and catheter-based technologies that address unmet needs in cardiac surgery and interventional cardiology. MID is focused on facilitating the paradigm shift from complex open surgical procedures to fully percutaneous, image-guided solutions
    BioSig Technologies
    BioSig is developing an advanced signal processing platform that will bring unmatched accuracy and precision into cardiac ablation and enhance treatment of arrhythmia. BioSig Technologies’ PURE EP system leverages low-noise proprietary hardware and software to capture subtle high-frequency signals. The platform’s enhanced cardiac signal intelligence and visualization equips the cardiologists and electrophysiologists with the most accurate and comprehensible cardiac information, enabling them to precisely locate erratic heart rhythms during cardiac ablation, without having to worry about interference or distortion.
    Anteris
    Anteris is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Their focus is on investing in and developing next-generation technologies with world class partners and acquiring strategic assets to grow product and service offerings
    Aria CV
    ARIA CV offers a novel implantable medical device designed to treat pulmonary hypertension, a progressive and deadly disease that impacts over 70 million people worldwide. Aria’s device is designed to treat a form of PH called World Health Organization (WHO) Group 1 PH, also known as Pulmonary Arterial Hypertension (PAH)
    B. Braun Group
    B. Braun Group is one of the world’s leading medical technology companies, which aims to protect and improve the health of people around the world. They support minimally invasive procedures in cardio-thoracic surgery with innovative medical technology solutions for clear access to the operating site, high-quality and high-precision micro-instruments, and advanced technology for 3D visualization
    Cardinal Health
    Cardinal Health manufactures and distributes medical and laboratory products for multiple healthcare segments, including cardiovascular health. The company is a market leader for cardiovascular monitoring, diagnostics, defibrillation, and neonatal electrodes
    General Electric
    General Electric delivers cutting-edge intelligent cardiovascular devices and data analytics solutions to cardiologists as well as other physicians deliver the best care to patients. To promote personalized health for cardiology, the company provides precision diagnostics, precision therapeutics, and precision monitoring, thus improving the outcomes for patients
    Kestra Medical Technologies
    Kestra Medical Technologies provides modern cardiac protection wearables for physicians suffering from cardiovascular diseases. The company's ASSURE Wearable Cardioverter Defibrillator (WCD) system, especially, is designed to help patients reduce the risk and achieve better health outcomes
    Leviticus Cardio
    Leviticus Cardio’s wireless power transfer technology, Coplanar Energy Transfer (CET), combined with an existing Ventricular Assist system, provides a new, robust, comprehensive hybrid solution for CHF patients. They have developed wireless power transfer system capable of providing the day-to-day power needs of available VAD implants
    Terumo Cardiovascular Systems Corporation
    Terumo Cardiovascular Systems Corporation develops, manufactures, and distributes medical devices for cardiac and vascular surgery with an emphasis on cardiopulmonary bypass, intra-operative monitoring and vascular grafting. This includes a full-line of perfusion products, endoscopic vessel harvesting products and surgical stabilization products

Cardiovascular Devices Info

Q1
What Do Cardiovascular Device Companies Do?
Cardiovascular device companies develop technologies used to diagnose, monitor and treat heart and vascular conditions. Their work can include implantable devices, rhythm management systems, vascular access tools, cardiac monitoring devices, structural heart technologies and procedure-support equipment. In a Top Cardiovascular Device Companies listing, the focus is not only on product novelty but also on clinical relevance, reliability, physician usability and patient safety. Hospitals and specialty practices often look for companies that understand both device performance and the realities of cardiac care delivery.
Q2
Why Do Top Cardiovascular Device Companies Matter Now?
Top cardiovascular device companies are becoming increasingly important as healthcare systems face growing pressure from aging populations, rising rates of chronic heart disease and demand for less invasive treatment options. Hospitals and care teams are looking for technologies that help detect problems earlier, reduce procedure time, improve patient monitoring and lower the risk of avoidable complications. Demand is also being driven by the expansion of outpatient care, remote monitoring and therapies designed for patients who may not be suitable for traditional surgical procedures. Because these devices operate so closely to patient risk and long-term outcomes, product reliability, regulatory discipline and strong clinical evidence remain critically important across the industry.
Q3
How Should Healthcare Decision-Makers Evaluate Cardiovascular Device Companies?
Evaluation should begin with the clinical problem the device addresses. A strong company should show credible evidence, clear indications for use, consistent manufacturing quality and practical fit within existing cardiology workflows. Decision-makers should also examine training requirements, service response, data handling, reimbursement alignment and supply continuity. Top Cardiovascular Device Companies are often judged by how well their products perform beyond controlled settings: in busy cath labs, electrophysiology suites, ambulatory monitoring programs and post-procedure follow-up.
Q4
What Value Do Cardiovascular Devices Create for Hospitals and Patients?
Cardiovascular devices can improve care by supporting faster diagnosis, more precise intervention and better long-term disease management. For hospitals, value may appear through fewer repeat procedures, better physician confidence, reduced monitoring gaps and stronger documentation. For patients, the impact may be felt in shorter recovery times, fewer clinic visits, earlier detection of rhythm changes or improved symptom control. Top Cardiovascular Device Companies earn attention when their technologies connect measurable clinical benefit with practical use by physicians, nurses and technicians.
Q5
How Are Technology and Expertise Changing the Cardiovascular Device Market?
The realm is extending beyond a standalone piece of hardware. Cardiac monitoring equipment is becoming increasingly reliant on software, secure data transmission, and physician dashboards/logic which needs to ignore noise but recognize a "meaningful" shift. Implantable and minimally invasive hardware needs to be robust and underpinned with robust engineering, material science and procedural understanding. While AI could help to manage signal processing and triaging, it must be carefully validated. Skillset remains important; something that looks technically advanced on paper will flop if it hinders procedures or is difficult for staff to learn.
Q6
What Should Healthcare Organizations Prioritize When Comparing Providers?
Healthcare organizations should prioritize clinical evidence, safety profile, ease of adoption, regulatory maturity, service quality and total cost of use. Procurement teams should also consider whether the company can support training, device availability, software updates and post-market surveillance. Top Cardiovascular Device Companies should be assessed through the lens of real cardiac care: procedure time, monitoring accuracy, physician learning curve, patient follow-up and integration with hospital systems. The strongest choice is rarely based on a single feature.